Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/5056
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRocha, Cláudia M.pt
dc.contributor.authorCarrola, Joanapt
dc.contributor.authorBarros, António S.pt
dc.contributor.authorGil, Ana M.pt
dc.contributor.authorGoodfellow, Brian J.pt
dc.contributor.authorCarreira, Isabel M.pt
dc.contributor.authorBernardo, Joaopt
dc.contributor.authorGomes, Anapt
dc.contributor.authorSousa, Vitorpt
dc.contributor.authorCarvalho, Linapt
dc.contributor.authorDuarte, Iola F.pt
dc.date.accessioned2012-01-11T17:06:29Z-
dc.date.available2013-02-05T15:48:35Z-
dc.date.issued2011-
dc.identifier.issn1535-3893pt
dc.identifier.urihttp://hdl.handle.net/10773/5056-
dc.description.abstractIn this work, the variations in the metabolic profile of blood plasma from lung cancer patients and healthy controls were investigated through NMR-based metabonomics, to assess the potential of this approach for lung cancer screening and diagnosis. PLS-DA modeling of CPMG spectra from plasma, subjected to Monte Carlo Cross Validation, allowed cancer patients to be discriminated from controls with sensitivity and specificity levels of about 90%. Relatively lower HDL and higher VLDL + LDL in the patients' plasma, together with increased lactate and pyruvate and decreased levels of glucose, citrate, formate, acetate, several amino acids (alanine, glutamine, histidine, tyrosine, valine), and methanol, could be detected. These changes were found to be present at initial disease stages and could be related to known cancer biochemical hallmarks, such as enhanced glycolysis, glutaminolysis, and gluconeogenesis, together with suppressed Krebs cycle and reduced lipid catabolism, thus supporting the hypothesis of a systemic metabolic signature for lung cancer. Despite the possible confounding influence of age, smoking habits, and other uncontrolled factors, these results indicate that NMR-based metabonomics of blood plasma can be useful as a screening tool to identify suspicious cases for subsequent, more specific radiological tests, thus contributing to improved disease management.pt
dc.description.sponsorshipERDF - Competitive Factors Thematic Operational Programmept
dc.description.sponsorshipFCT/PTDC/ QUI/68017/2006pt
dc.description.sponsorshipFCOMP-01-0124-FEDER-007439pt
dc.description.sponsorshipSFRH/BD/ 63430/2009pt
dc.description.sponsorshipNational UNESCO Committee - L'Oréal Medals of Honor for Women in Science 200pt
dc.description.sponsorshipPortuguese National NMR Network - RNRMNpt
dc.language.isoengpt
dc.publisherAmerican Chemical Societypt
dc.relationdx.doi.org/10.1021/pr200550ppt
dc.rightsopenAccesspor
dc.subjectlung cancerpt
dc.subjectNMR spectroscopypt
dc.subjectmetabonomicspt
dc.subjectblood plasmapt
dc.subjectmetabolic profilept
dc.titleMetabolic Signatures of Lung Cancer in Biofluids: NMR-Based Metabonomics of Blood Plasmapt
dc.typearticlept
dc.peerreviewedyespt
ua.distributioninternationalpt
degois.publication.firstPage4314pt
degois.publication.issue9-
degois.publication.issue9pt
degois.publication.lastPage4324pt
degois.publication.titleJournal of Proteome Researchpt
degois.publication.volume10pt
Appears in Collections:DQ - Artigos

Files in This Item:
File Description SizeFormat 
J Proteome Res 2011 Rocha.pdf1.62 MBAdobe PDFView/Open


FacebookTwitterLinkedIn
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.